AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.

Also called NCT05035277

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 360 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05035277
  • EudraCT 2021-001554-61
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Norway (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05035277. Randomized; single masking; primary purpose prevention. Start 2021-12-04 (actual); primary completion 2026-06-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
Acronym
ACASA-TAVI
Condition
Aortic Stenosis
Intervention (Drug)
Acetylsalicylic acid
Intervention (Drug)
Apixaban
Intervention (Drug)
Rivaroxaban
Intervention (Drug)
Edoxaban
Lead sponsor
Oslo University Hospital (class: other)
Collaborator
University of Oslo (class: other)

Record details

Record id
cardio:ct-nct05035277
Content hash
fe4644b1a7b9205494c33172a213708294d4256708d9b99cf3c6c80fef063cb4